Wedbush Lowers Generation Bio Price Target to $5.50
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Wedbush lowered the firm's price target on Generation Bio (GBIO) to $5.50 from $7 and keeps a Neutral rating on the shares. Xoma (XOMA) will acquire Generation Bio for $4.2913/share plus a non-transferable CVR, with an expected close in February 2026. The firm expects the transaction to proceed and does not anticipate other bidders. The CVR will include cash at closing in excess of $28.97M, 90%-100% of savings on Generation Bio's office lease obligations, a share of milestone and royalty payments from Moderna (MRNA), and a share of payments from out-license or sale of the ctLNP delivery platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 72.500
Low
17.00
Averages
32.47
High
63.00
Current: 72.500
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna's Evolving Pipeline Sparks Long-Term Investment Interest
- Pipeline Expansion: Moderna is expanding into treatments for cancer and other diseases, providing a new long-term investment rationale despite many programs being years away from commercialization.
- Strong Stock Performance: Moderna's stock has surged nearly 150% this year, making it one of the best performers in the S&P 500, although it remains below its pandemic peak of $484 in August 2021.
- Science Day Strategy Reveal: At last week's Science Day, Moderna presented a detailed roadmap for the next decade, highlighting the growth of its cancer pipeline and new vaccine programs, indicating a clear path to profitability.
- Significant Cancer Treatment Progress: Moderna has made notable advancements in mid and late-stage trials for various cancers, particularly the expected results from a late-stage study of its Intismeran combined with Merck's Keytruda for melanoma, marking a significant strategic shift for the company.
See More
PANW, AAL, MRNA Stocks Surge Amid Optimism
- PANW Stock Surge: Palo Alto Networks (PANW) stock jumped over 3% to a 52-week high of $358.10, driven by Wells Fargo and BTIG raising their price targets to $420 and $380 respectively, reflecting strong confidence in product demand and likely enhancing the company's market share in cybersecurity.
- AAL Stock Rise: American Airlines Group (AAL) stock closed up 0.44%, reaching an annual high of $18.47, buoyed by falling global oil prices and robust travel demand, with Bernstein and BofA analysts raising their price targets to $23 and $19, indicating a positive outlook for the company's performance.
- MRNA Stock Climb: Moderna (MRNA) stock increased over 3%, hitting a new high of $73.91, following the announcement of a new strategy at Science Day to expand its mRNA platform to include infectious disease vaccines, cancer vaccines, and rare disease therapeutics, which is expected to drive future revenue growth.
- Market Sentiment Shift: As PANW, AAL, and MRNA stocks rise, retail investor sentiment has shifted from neutral to bullish, particularly with MRNA surging 134.93% in 2026, highlighting significant market interest in its new products and strategies.
See More
Moderna's Expanding Pipeline Sparks Investor Interest
- Product Line Expansion: Moderna's stock has surged nearly 150% over the past year, making it one of the best performers in the S&P 500, reflecting strong market confidence in its new product lines, although it remains below the pandemic peak of $484 in 2021.
- Cancer Treatment Progress: The company's efforts in cancer therapies have garnered investor attention, with mid and late-stage trials targeting melanoma and non-small cell lung cancer underway, with significant study results expected later this year that could drive new growth.
- Vaccine Development Advances: Moderna's experimental flu vaccine received a recommendation from the FDA advisory committee, with a regulatory decision expected on August 5, while its combination Covid and flu vaccine has been approved by the European Commission, enhancing the diversity of its product portfolio.
- Future Outlook: Cramer highlighted that Moderna has presented a clear roadmap to profitability for the first time, emphasizing its potential in cancer and vaccine sectors, and while it may take years to realize, the company's future outlook remains optimistic, advising investors to wait for the right buying opportunity.
See More
FDA Revives Advisory Committee Meetings for Drug Approvals
- Advisory Committee Revival: The FDA is reviving its Advisory Committee meetings under new leadership to reassess controversial decisions made during Marty Makary's tenure, which is expected to enhance the transparency and scientific rigor of drug approvals.
- Replimune and Capricor Reviews: Replimune (REPL) and Capricor Therapeutics (CAPR) are set for FDA advisory committee reviews at the end of July, with Replimune's RP1 targeting melanoma and Capricor's Deramiocel aimed at Duchenne muscular dystrophy, potentially impacting their market performance.
- Moderna Vaccine Endorsement: Moderna (MRNA) has received unanimous backing from the FDA's Vaccines Advisory Committee for its flu vaccine mRNA-1010, currently under review with a target action date of August 5, indicating strong competitive positioning in the vaccine market.
- Hims & Hers Market Potential: Hims & Hers Health (HIMS) is expected to benefit from an upcoming advisory committee meeting, which could allow it to capture one-fifth of the telehealth peptide market projected to reach $2.2 billion by 2027, although market performance remains uncertain.
See More
Moderna's Stock Surges Nearly 150% Amid Regulatory Progress
- Vaccine Regulatory Progress: On June 18, Moderna revealed that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating that the benefits outweigh the risks for patients aged 50 and over, with potential FDA approval by August 5, which could significantly enhance the company's competitive position in the flu vaccine market.
- Sentiment Boost: The recent investor day included a surprise announcement regarding the development of an in vivo CAR-T candidate, which, if successful, could diversify Moderna's product line into respiratory, oncology, and rare disease treatments, thereby enhancing future revenue potential.
- Valuation Risks: Despite the bullish sentiment, Moderna's market cap has reached $26.7 billion while remaining unprofitable, indicating that this valuation is heavily reliant on the future potential of its non-COVID-19 products, with the total addressable market for flu vaccines estimated at only $9.5 billion, necessitating a dominant market share for profitability.
- Increased Financing Risks: As Moderna continues to burn through cash to fund its post-COVID-19 recovery, the risk of a dilutive equity offering rises, and while there is optimism about its long-term rebound potential, investors may need to exercise caution until the recent hype subsides.
See More
Moderna's mRNA Flu Vaccine Gains FDA Support
- Vaccine Development Progress: On June 18, Moderna announced that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating significant market potential among patients aged 50 and over, with FDA approval expected by August 5, potentially opening new revenue streams for the company.
- Market Rebound Dynamics: Despite Moderna's stock price surging nearly 150% over the past year to a market cap of $26.7 billion, analysts caution that much of this recovery potential is already priced in, and future profitability will depend on capturing market share in non-COVID-19 products.
- Diversification Strategy: The company unexpectedly announced plans to develop an in vivo CAR-T candidate during its recent investor day, which, if successful, could help Moderna diversify into respiratory, oncology, and rare disease treatments, enhancing its competitive position in the market.
- Financial Risk Warning: While market sentiment remains bullish, Moderna faces risks related to cash burn and may need to pursue dilutive equity offerings to fund its post-COVID-19 recovery, prompting investors to carefully consider their timing for entry.
See More
Moderna's Evolving Pipeline Sparks Long-Term Investment Interest
- Pipeline Expansion: Moderna is expanding into treatments for cancer and other diseases, providing a new long-term investment rationale despite many programs being years away from commercialization.
- Strong Stock Performance: Moderna's stock has surged nearly 150% this year, making it one of the best performers in the S&P 500, although it remains below its pandemic peak of $484 in August 2021.
- Science Day Strategy Reveal: At last week's Science Day, Moderna presented a detailed roadmap for the next decade, highlighting the growth of its cancer pipeline and new vaccine programs, indicating a clear path to profitability.
- Significant Cancer Treatment Progress: Moderna has made notable advancements in mid and late-stage trials for various cancers, particularly the expected results from a late-stage study of its Intismeran combined with Merck's Keytruda for melanoma, marking a significant strategic shift for the company.
See More
PANW, AAL, MRNA Stocks Surge Amid Optimism
- PANW Stock Surge: Palo Alto Networks (PANW) stock jumped over 3% to a 52-week high of $358.10, driven by Wells Fargo and BTIG raising their price targets to $420 and $380 respectively, reflecting strong confidence in product demand and likely enhancing the company's market share in cybersecurity.
- AAL Stock Rise: American Airlines Group (AAL) stock closed up 0.44%, reaching an annual high of $18.47, buoyed by falling global oil prices and robust travel demand, with Bernstein and BofA analysts raising their price targets to $23 and $19, indicating a positive outlook for the company's performance.
- MRNA Stock Climb: Moderna (MRNA) stock increased over 3%, hitting a new high of $73.91, following the announcement of a new strategy at Science Day to expand its mRNA platform to include infectious disease vaccines, cancer vaccines, and rare disease therapeutics, which is expected to drive future revenue growth.
- Market Sentiment Shift: As PANW, AAL, and MRNA stocks rise, retail investor sentiment has shifted from neutral to bullish, particularly with MRNA surging 134.93% in 2026, highlighting significant market interest in its new products and strategies.
See More
Moderna's Expanding Pipeline Sparks Investor Interest
- Product Line Expansion: Moderna's stock has surged nearly 150% over the past year, making it one of the best performers in the S&P 500, reflecting strong market confidence in its new product lines, although it remains below the pandemic peak of $484 in 2021.
- Cancer Treatment Progress: The company's efforts in cancer therapies have garnered investor attention, with mid and late-stage trials targeting melanoma and non-small cell lung cancer underway, with significant study results expected later this year that could drive new growth.
- Vaccine Development Advances: Moderna's experimental flu vaccine received a recommendation from the FDA advisory committee, with a regulatory decision expected on August 5, while its combination Covid and flu vaccine has been approved by the European Commission, enhancing the diversity of its product portfolio.
- Future Outlook: Cramer highlighted that Moderna has presented a clear roadmap to profitability for the first time, emphasizing its potential in cancer and vaccine sectors, and while it may take years to realize, the company's future outlook remains optimistic, advising investors to wait for the right buying opportunity.
See More
FDA Revives Advisory Committee Meetings for Drug Approvals
- Advisory Committee Revival: The FDA is reviving its Advisory Committee meetings under new leadership to reassess controversial decisions made during Marty Makary's tenure, which is expected to enhance the transparency and scientific rigor of drug approvals.
- Replimune and Capricor Reviews: Replimune (REPL) and Capricor Therapeutics (CAPR) are set for FDA advisory committee reviews at the end of July, with Replimune's RP1 targeting melanoma and Capricor's Deramiocel aimed at Duchenne muscular dystrophy, potentially impacting their market performance.
- Moderna Vaccine Endorsement: Moderna (MRNA) has received unanimous backing from the FDA's Vaccines Advisory Committee for its flu vaccine mRNA-1010, currently under review with a target action date of August 5, indicating strong competitive positioning in the vaccine market.
- Hims & Hers Market Potential: Hims & Hers Health (HIMS) is expected to benefit from an upcoming advisory committee meeting, which could allow it to capture one-fifth of the telehealth peptide market projected to reach $2.2 billion by 2027, although market performance remains uncertain.
See More
Moderna's Stock Surges Nearly 150% Amid Regulatory Progress
- Vaccine Regulatory Progress: On June 18, Moderna revealed that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating that the benefits outweigh the risks for patients aged 50 and over, with potential FDA approval by August 5, which could significantly enhance the company's competitive position in the flu vaccine market.
- Sentiment Boost: The recent investor day included a surprise announcement regarding the development of an in vivo CAR-T candidate, which, if successful, could diversify Moderna's product line into respiratory, oncology, and rare disease treatments, thereby enhancing future revenue potential.
- Valuation Risks: Despite the bullish sentiment, Moderna's market cap has reached $26.7 billion while remaining unprofitable, indicating that this valuation is heavily reliant on the future potential of its non-COVID-19 products, with the total addressable market for flu vaccines estimated at only $9.5 billion, necessitating a dominant market share for profitability.
- Increased Financing Risks: As Moderna continues to burn through cash to fund its post-COVID-19 recovery, the risk of a dilutive equity offering rises, and while there is optimism about its long-term rebound potential, investors may need to exercise caution until the recent hype subsides.
See More
Moderna's mRNA Flu Vaccine Gains FDA Support
- Vaccine Development Progress: On June 18, Moderna announced that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating significant market potential among patients aged 50 and over, with FDA approval expected by August 5, potentially opening new revenue streams for the company.
- Market Rebound Dynamics: Despite Moderna's stock price surging nearly 150% over the past year to a market cap of $26.7 billion, analysts caution that much of this recovery potential is already priced in, and future profitability will depend on capturing market share in non-COVID-19 products.
- Diversification Strategy: The company unexpectedly announced plans to develop an in vivo CAR-T candidate during its recent investor day, which, if successful, could help Moderna diversify into respiratory, oncology, and rare disease treatments, enhancing its competitive position in the market.
- Financial Risk Warning: While market sentiment remains bullish, Moderna faces risks related to cash burn and may need to pursue dilutive equity offerings to fund its post-COVID-19 recovery, prompting investors to carefully consider their timing for entry.
See More
